pp-178 Tablets, enteric coated
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Prevention of COVID-19 (adults; primary or booster immunisation)
Clinical stage: Phase 2
Modality: Biologic (recombinant adenovirus type 5 oral tablet vaccine encoding SARS-CoV-2 spike)
Mechanism / Target: Adenovirus 5 vector delivers SARS-CoV-2 spike antigen to intestinal mucosa — induces mucosal IgA (nasal/lung), systemic IgG and T-cell immunity; broader mucosal protection potential vs injectable mRNA
Route / form: Oral tablet (enteric-coated; room-temperature stable)
Differentiation: Oral delivery may induce nasal/lung IgA reducing transmission; thermostable — no cold chain; supports needle-free vaccination; unique mucosal immunity profile vs mRNA vaccines
Manufacturer #39196
Clinical-stage vaccine company pioneering oral tablet vaccines using an adenovirus vector platform. Develops thermostable, room-temperature-stable oral vaccines to replace injectable immunisations. Wholly owned norovirus and COVID-19 oral vaccine programmes advancing in Phase 2.
None